BCL2 (AAA) Jurkat; Acute T Cell Leukemia; Human (Homo sapiens) Item ID: ATCCRL2902
| Permits and Restrictions |
View Permits |
|---|---|
| Organism | Homo sapiens, human |
| Tissue | peripheral blood |
| Cell Type | T Cell/ T Lymphocyte |
| Product Format | frozen |
| Morphology | Lymphoid-like |
| Culture Properties | suspension |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | acute T cell leukemia |
| Age | 14 years |
| Gender | male |
| Applications |
This cell line is useful to study cell apoptosis, BCL-2 function and its pathway, as well as phosphorylation of BCL-2. |
| Storage Conditions | liquid nitrogen vapor phase |
| Images | |
|---|---|
| Derivation |
The BCL2 (AAA) Jurkat cell line was derived by transfecting human Jurkat T cells with the pSFFV-neo mammalian expression vector containing the human BCL2 mutated ORF insert and a neomycin-resistant gene (Parental vector: Addgene # 3349). BCL2 (AAA) stable neomycin (Neo)-resistant single-cell-originated clones were isolated and expanded by selection in medium containing 1 mg/mL G418 for 14 days |
| Tumorigenic | Yes |
| Comments |
The BCL2 (AAA) Jurkat cell line was derived by transfecting human Jurkat T cells with the pSFFV-neo mammalian expression vector containing the human BCL2 mutated ORF insert and a neomycin-resistant gene (Parental vector: Addgene # 3349). The BCL2 (AAA) Jurkat cells contain the BCL2 ORF with a triple sub-mutation at Thr69, Ser70, and Ser87. These amino acids have been replaced with Alanine at their respective positions. BCL2 (AAA) stable neomycin (Neo)-resistant single-cell-originated clones were isolated and expanded by selection in medium containing 1 mg/mL G418 for 14 days. The BCL2 (AAA) Jurkat cell line overexpresses the AA/A-mutated form of Bcl-2. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: 10% FBS and 200 mcg/mL G418. |
|---|---|
| Subculturing |
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 x 105 viable cells/mL. Do not allow the cell density to exceed 3 x 106 cells/mL. Subcultivation ratio: Maintain cultures at a cell concentration between between 1 x 105 and 1 x 106 viable cells/mL.Medium renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation | Freeze medium: 90% Fetal Bovine Serum and 10% DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Temperature: 37°CAtmosphere: air, 95%; carbon dioxide (CO2), 5% |
| STR Profile | D5S818: 9 D13S317: 8, 12 D7S820: 8, 12 D16S539: 11 vWA: 18 TH01: 6, 9.3 Amelogenin: X Y TPOX: 7, 10, 11 CSF1PO: 11 |
|---|
| Name of Depositor | Stanley Korsmeyer |
|---|---|
| Year of Origin | 2002 |
| References |
Yamamoto K, et al. BCL-2 is Phosphorylated and Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway normally Activated at G2/M. Mol Cell Biol. Dec;19(12):8469-78. 1999. PubMed: 10567572 Bassik MC, et al. Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis. Embo J. March 10; 23(5): 1207–1216. 2004. PubMed: 15010700 |
| Permits |
These permits may be required for shipping this product to Australia:
|
|---|---|
| Basic Documentation | Product Sheet Certificate of Analysis SDS |
| Other Documentation | Cell Micrograph |
| References |
Yamamoto K, et al. BCL-2 is Phosphorylated and Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway normally Activated at G2/M. Mol Cell Biol. Dec;19(12):8469-78. 1999. PubMed: 10567572 Bassik MC, et al. Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis. Embo J. March 10; 23(5): 1207–1216. 2004. PubMed: 15010700 |